Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,187
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
An open label, phase 1 study to evaluate the safety, feasibility and immunogenicity of an allogeneic, cell-based vaccine (VIDIDENCEL) in high grade serous ovarian cancer patients after primary treatment (ALISON)
Disc Medicine
High grade serous ovarian cancer
1 trial -
Bio-equivalence of Rosuvastatin 10 mg
Disc Medicine
Healthy volunteers
1 trial -
Click-cleavable imaging in HER2-positive cancers (CleavHER trial).
Disc Medicine
HER2-positive tumors
1 trial -
Coadministration of GA2 Sporozoites With Adjuvants (CoGA)
Disc Medicine
Falciparum malaria
1 trial -
Combining drug-eluting bead chemoembolization and radioembolization for treatment of colorectal liver metastases: DEBIR90Y study
Disc Medicine
colorectal liver metastases
1 trial -
DISC-0974
Disc Medicine
Chronic Kidney Diseases
1 trial -
DISC-0974
Disc Medicine
Healthy Volunteer
1 trial -
DISC-3405
Disc Medicine
Healthy Volunteer
1 trial -
DISC-3405
Disc Medicine
Sickle Cell Disease
1 trial -
Dendritic cell therapy combined with surgery in mesothelioma (ENSURE)
Disc Medicine
Adult patients diagnosed with resectable epithelioid MPM, following first-line chemotherapy.
1 trial -
Detection of tumor tiSsue in pEritoneal metastases of coLorectal origin using a VEGF-targeted optical fluoresCent imaging tracer during diagnosTic laparoscopy
Disc Medicine
peritoneal metastases of colorectal origin
1 trial -
Dual-Wavelength Quantitative Fluorescence Endoscopy for Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer: A Phase I Multicenter Feasibility and Safety Study
Disc Medicine
Esophageal cancer
1 trial -
Evaluating PD-1/PD-L1 in rectal cancer by quantitative fluorescence molecular endoscopy.
Disc Medicine
Locally advanced rectal cancer
1 trial -
Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104 (HEB-PEP)
Disc Medicine
chronic Hepatitis B
1 trial -
GRoningen Early-PD Ambroxol Treatment Pharmacokinetics
Disc Medicine
Parkinson's disease
1 trial -
INTERACT MESO: Intraperitoneal Paclitaxel for Patients with Primary Malignant Peritoneal Mesothelioma – a Phase I/II Dose Escalation and Safety Study
Disc Medicine
Patients with malignant peritoneal mesothelioma
1 trial -
INTERACT stomach
Disc Medicine
Stomach Cancer with metastasis in the peritoneum
1 trial -
Improving Peptide Receptor Radionuclide Therapy with PARP inhibitors
Disc Medicine
locally advanced or metastatic, well-differentiated gastro-enteropancreatic neuroendocrine tumors.
1 trial -
Irinotecan Accord 20 mg/ml concentraat voor oplossing voor infusie
Disc Medicine
Gastric cancer
1 trial -
MCA-derived MSC therapy in renal transplant recipients
Disc Medicine
Rejection transplanted kidney, BPAR
1 trial -
MIRROR; Multispectral and bimodal fluorescent guided surgery (FGS) of high-grade glioma for refining margin assessment: A phase 1 dose finding study using Cetuximab-IRDye800CW- combined with 5-ALA
Disc Medicine
Glioblastoma
1 trial -
Molecular imaging with FAPI for diagnosing the CSM4 colorectal cancer subtype
Disc Medicine
Colorectal cancer, liver metastases
1 trial -
Optical PD-L1 imaging using Quantitative Fluorescence Endoscopy in locally advanced esophageal cancer using durvalumab-680LT: a phase I multicenter feasibility and safety study
Disc Medicine
Esophageal cancer
1 trial -
Oxytocine and migraine
Disc Medicine
This is a study in healthy volunteers. We will study the trigeminovascular system, which is relevant in the pathophysiology of migraine.
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources